Local delivery of CER-001 in advanced plaques Proof-of-concept for apoA-1 as initiator of reverse cholesterol transport (LOCATION)
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
Price : $35 *
At a glance
- Drugs CER 001 (Primary)
- Indications Hypoalphalipoproteinaemia
- Focus Proof of concept; Therapeutic Use
- Acronyms LOCATION
- 12 Mar 2016 Status changed from active, no longer recruiting to completed.
- 15 Jul 2015 Status changed from recruiting to active, no longer recruiting, based on information in Cerenis Therapeutics media release.
- 15 Jul 2015 Results published in the Media Release.